Individualiserad behandling vid ovarialcancer kan bli möjlig
Sammanfattning
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy in developed countries. Several promising steps toward
individualized therapy have been taken recently due to increased knowledge of molecular biology. Multidisciplinary conferences for treatment
planning and the centralization to tertiary surgical centers improve quality of surgery and survival. The primary treatment of EOC is radical
surgery followed by adjuvant chemotherapy with carboplatin and paclitaxel. Bevacizumab added to the chemotherapy and used as maintenance
treatment is standard in the primary treatment of patients with residual tumor or inoperable patients. The PARP inhibitor olaparib is recommended
as maintenance treatment of women with platinum sensitive relapsed BRCA mutated high-grade serous EOC who have responded to platinum-
based chemotherapy. BRCA testing should be offered to women with EOC. In platinum-resistant recurrence addition of bevacizumab to
chemotherapy should be considered.